Blockade of TRAIL pathway ameliorates HBV-induced hepatocyte apoptosis in an acute hepatitis model

被引：29
作者：
Liu, Yu-Gang
Liu, Su-Xia
Liang, Xiao-Hong
Zhang, Qiu
Gao, Li-Fen
Han, Li-Hui
Cao, Ying-Lin
Hou, Nan
Du, Juan
Sun, Wen-Sheng
机构：
[1] Shandong Univ, Sch Med, Inst Immunol, Jinan 250012, Peoples R China
[2] Shandong Univ, Inst Environm Res, Jinan 250100, Peoples R China
来源：
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS | 2007年 / 352卷 / 02期
基金：
中国国家自然科学基金;
关键词：
tumor necrosis factor (TNF)-related apoptosis-inducing ligand (TRAIL); soluble death receptor 5 (sDR5); apoptosis; hepatitis B virus (HBV); fulminant hepatitis; Stronger Neo-Minophagen C (SNMC);
D O I：
10.1016/j.bbrc.2006.11.024
中图分类号：
Q5 [生物化学]; Q7 [分子生物学];
学科分类号：
071010 ; 081704 ;
摘要：
Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) may play important roles during hepatitis B virus (HBV) infection. In this study, we used a recombinant human soluble death receptor 5 (sDR5) to explore its effect in a mouse model of HBV-induced acute hepatitis. By measuring blood transaminase activity and hepatocyte apoptosis, we found that sDR5 could alleviate liver damage by blocking TRAIL-induced apoptosis of HBV-transfected hepatocytes. sDR5 injection at 16 mg/kg 24 h before HBV transfection was the most effective. Additionally, we showed that sDR5 was equally effective in protecting liver injury as the Stronger Neo-Minophagen C (SNMC), a commonly used drug for patients with liver diseases. Thus, sDR5 represents a potential novel therapeutic drug for patients with fulminant hepatitis. (c) 2006 Elsevier Inc. All rights reserved.
引用
收藏
页码：329 / 334
页数：6
相关论文
共 22 条
[1]   Mice lacking TNFα receptors 1 and 2 are resistant to death and fulminant liver injury induced by agonistic anti-Fas antibody [J].
Costelli, P ;
Aoki, P ;
Zingaro, B ;
Carbó, N ;
Reffo, P ;
Lopez-Soriano, FJ ;
Bonelli, G ;
Argilés, JM ;
Baccino, FM .
CELL DEATH AND DIFFERENTIATION, 2003, 10 (09) :997-1004
[2]   The novel receptor TRAIL-R4 induces NF-κB and protects against TRAIL-mediated apoptosis, yet retains an incomplete death domain [J].
Degli-Esposti, MA ;
Dougall, WC ;
Smolak, PJ ;
Waugh, JY ;
Smith, CA ;
Goodwin, RG .
IMMUNITY, 1997, 7 (06) :813-820
[3]   Osteoprotegerin is a receptor for the cytotoxic ligand TRAIL [J].
Emery, JG ;
McDonnell, P ;
Burke, MB ;
Deen, KC ;
Lyn, S ;
Silverman, C ;
Dul, E ;
Appelbaum, ER ;
Eichman, C ;
DiPrinzio, R ;
Dodds, RA ;
James, IE ;
Rosenberg, M ;
Lee, JC ;
Young, PR .
JOURNAL OF BIOLOGICAL CHEMISTRY, 1998, 273 (23) :14363-14367
[4]  
HAN L, 2002, CHIN MED J, V82, P597
[5]   Therapy of viral hepatitis [J].
Hoofnagle, JH .
DIGESTION, 1998, 59 (05) :563-578
[6]   Therapeutic effects of stronger neo-minophagen C at different doses on chronic hepatitis and liver cirrhosis [J].
Iino, S ;
Tango, T ;
Matsushima, T ;
Toda, G ;
Miyake, K ;
Hino, K ;
Kumada, H ;
Yasuda, K ;
Kuroki, T ;
Hirayama, C ;
Suzuki, H .
HEPATOLOGY RESEARCH, 2001, 19 (01) :31-40
[7]   Essential roles of the Fas ligand in the development of hepatitis [J].
Kondo, T ;
Suda, T ;
Fukuyama, H ;
Adachi, M ;
Nagata, S .
NATURE MEDICINE, 1997, 3 (04) :409-413
[8]  
Ksontini R, 1998, J IMMUNOL, V160, P4082
[9]   Hydrodynamics-based transfection in animals by systemic administration of plasmid DNA [J].
Liu, F ;
Song, YK ;
Liu, D .
GENE THERAPY, 1999, 6 (07) :1258-1266
[10]  
Loomba R, 2006, ANTIVIR THER, V11, P1
123